Statement: the primary trial only recorded three types of adverse events.
Primary_evidence: Adverse Events 1:   Total: 3/30 (10.00%)   Cholecystitis *  [1]1/30 (3.33%)   Increase in diarrhea *  [2]1/30 (3.33%)   Flank pain *  [3]1/30 (3.33%)